Topline data: In long-term follow-up of MODERATO II participants (n=16; mean 3.6 years), atrioventricular interval modulation (AVIM) maintained a 24-hour ambulatory systolic blood pressure reduction of 8.9 mmHg (p<0.001). A seven-day deactivation returned aSBP to baseline (≈133 mmHg) without rebound, and reactivation immediately reduced aSBP to 124.4 mmHg (p<0.002). The magnitude was consistent with earlier signals, including the randomized pilot’s net reductions at six months of 8.1 mmHg in aSBP and 12.3 mmHg in office SBP. The news: Orchestra BioMed presented mechanistic and clinical data at HRX Live 2025, paired with a peer-reviewed publication, supporting AVIM as a pacemaker-deliverable, programmable therapy for uncontrolled hypertension. The program is part of a strategic collaboration with Medtronic and holds an FDA Breakthrough Device designation. AVIM is now being evaluated in BACKBEAT, a global pivotal trial targeting patients with systolic blood pressure above goal despite medication who are indicated for, or recently received, a dual-chamber pacemaker. Strategically, this is a targeted expansion play that leverages an under-penetrated intersection: hypertensive patients who are already undergoing pacemaker implantation.
Rather than competing head-on with renal denervation and next-line polypharmacy across the broader population of resistant hypertension, AVIM leverages an existing implantable platform and electrophysiology channel, positioning blood pressure control as an incremental capability of standard pacemaker hardware. The durability, reversibility, and reproducibility signals address a key regulatory and payer concern for device-based hypertension therapies: consistent, controllable effect without long-term safety trade-offs. The tension is the dataset’s size and provenance; the long-term cohort is small and derived from a pilot trial, and the on–off–on observations, while compelling mechanistically, still require confirmation at scale under blinded conditions with medication optimization and standardized ABPM. For sites and CROs, the pivotal program pushes hypertension outcomes deeper into EP labs and dual-specialty workflows. Centers will require rigorous ABPM logistics, medication stabilization, and standardization of programming, as well as close coordination between device clinic staff and hypertension teams. The operational upside is that AVIM can be layered onto routine pacemaker care pathways without requiring new implant infrastructure; however, battery management, pacing burden, and arrhythmia surveillance become operational endpoints as much as clinical ones. For sponsors and regulators, the approach tests whether ambulatory BP change can anchor labeling for a pacemaker-based algorithm, and whether cardiovascular outcomes will be required for broader claims. Payers and hospital value analysis committees will scrutinize incremental costs within pacemaker DRGs, including coding for programming, and any offsets in drug burden or hospitalization risk. Vendors across ABPM and remote monitoring stand to benefit if ambulatory measurement becomes a central component of both trial endpoints and post-implant management. What’s next: The pivotal trial’s design choices will be decisive—control strategy (sham programming versus usual pacing), primary endpoint timing, medication run-in rigor, predefined safety metrics on device longevity and atrial/ventricular arrhythmia, and subgroup performance in patients with conduction disease. Timelines for Medtronic platform integration and global regulatory pathways under MDR will shape site uptake. Competitive context also matters: renal denervation is gaining traction with similar-order aSBP reductions, and convergence scenarios—AVIM for pacemaker recipients, denervation for non-pacemaker candidates—may define segmentation rather than head-to-head displacement. Watch enrollment velocity across EP-heavy networks, interim ABPM readouts, battery longevity data, and early payer feedback on programming reimbursement. The unresolved questions are whether AVIM can demonstrate reproducible benefit at scale under blinded conditions, how durable the signal remains across device generations, and whether regulators will ultimately expect event-driven evidence beyond blood pressure.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
